Analysts Anticipate Lumos Pharma, Inc. (NASDAQ:LUMO) Will Post Earnings of -$1.06 Per Share

Wall Street brokerages forecast that Lumos Pharma, Inc. (NASDAQ:LUMO) will announce ($1.06) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Lumos Pharma’s earnings, with the highest EPS estimate coming in at ($1.02) and the lowest estimate coming in at ($1.11). Lumos Pharma reported earnings of $0.21 per share during the same quarter last year, which suggests a negative year over year growth rate of 604.8%. The firm is expected to report its next quarterly earnings results on Tuesday, November 9th.

According to Zacks, analysts expect that Lumos Pharma will report full-year earnings of ($4.25) per share for the current fiscal year, with EPS estimates ranging from ($4.39) to ($4.10). For the next financial year, analysts forecast that the business will post earnings of ($4.82) per share, with EPS estimates ranging from ($5.72) to ($3.77). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Lumos Pharma.

Lumos Pharma (NASDAQ:LUMO) last issued its quarterly earnings results on Thursday, August 5th. The company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by ($0.03). Lumos Pharma had a negative return on equity of 16.13% and a negative net margin of 3,370.83%. The business had revenue of $0.01 million for the quarter.

A number of research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Lumos Pharma from a “hold” rating to a “sell” rating in a research note on Friday, July 23rd. Jonestrading restated a “buy” rating and set a $25.00 target price on shares of Lumos Pharma in a research note on Friday, August 6th. HC Wainwright decreased their price target on shares of Lumos Pharma from $34.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, July 21st. Finally, Roth Capital decreased their price target on shares of Lumos Pharma from $51.00 to $35.00 and set a “buy” rating on the stock in a research note on Thursday, July 22nd. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $28.60.

Shares of LUMO traded down $0.26 during trading hours on Monday, reaching $9.90. 14,366 shares of the stock traded hands, compared to its average volume of 52,243. Lumos Pharma has a 52-week low of $7.23 and a 52-week high of $36.72. The company’s 50-day moving average price is $9.29 and its two-hundred day moving average price is $10.58. The company has a market cap of $82.73 million, a P/E ratio of -4.66 and a beta of 1.74.

In other Lumos Pharma news, Director Kevin M. Lalande purchased 35,679 shares of the stock in a transaction dated Friday, August 20th. The stock was purchased at an average price of $8.73 per share, with a total value of $311,477.67. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kevin M. Lalande purchased 31,000 shares of the stock in a transaction dated Thursday, August 12th. The stock was acquired at an average cost of $7.55 per share, with a total value of $234,050.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 215,544 shares of company stock worth $1,949,463 over the last quarter. 17.50% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in Lumos Pharma by 2.9% during the 1st quarter. BlackRock Inc. now owns 71,078 shares of the company’s stock valued at $831,000 after purchasing an additional 2,017 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Lumos Pharma by 65.0% in the first quarter. Acadian Asset Management LLC now owns 5,879 shares of the company’s stock worth $69,000 after acquiring an additional 2,315 shares during the period. Renaissance Technologies LLC increased its stake in shares of Lumos Pharma by 7.6% in the first quarter. Renaissance Technologies LLC now owns 332,419 shares of the company’s stock worth $3,889,000 after acquiring an additional 23,607 shares during the period. Opaleye Management Inc. increased its stake in shares of Lumos Pharma by 34.0% in the first quarter. Opaleye Management Inc. now owns 376,900 shares of the company’s stock worth $4,410,000 after acquiring an additional 95,613 shares during the period. Finally, Marquette Asset Management LLC acquired a new stake in shares of Lumos Pharma in the second quarter worth $89,000. 38.36% of the stock is owned by institutional investors.

About Lumos Pharma

Lumos Pharma, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Featured Story: Trading Ex-Dividend Strategy

Get a free copy of the Zacks research report on Lumos Pharma (LUMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lumos Pharma (NASDAQ:LUMO)

Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.